Roberto Ferrari1,2,3, J Cardoso4,5,6, M C Fonseca7,8, C Aguiar9, J I Moreira10, A Fucili11, C Rapezzi12. 1. University Cardiologic Centre, University Hospital of Ferrara, Ferrara, Italy. fri@unife.it. 2. Maria Cecilia Hospital, Cotignola, Italy. fri@unife.it. 3. Azienda Ospedaliero-Universitaria di Ferrara, Ospedale di Cona, Via Aldo Moro 8, Cona, 44124, Ferrara, Italy. fri@unife.it. 4. CINTESIS-Center for Health Technology and Services Research, Porto, Portugal. 5. Department of Cardiology, Faculty of Medicine, University of Porto, Porto, Portugal. 6. São João Medical Centre, Porto, Portugal. 7. Heart Failure Clinic, Hospital São Francisco Xavier, CHLO, Lisbon, Portugal. 8. NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. 9. Advanced Heart Failure Unit, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal. 10. CHTMAD, Hospital S. Pedro, Vila Real, Portugal. 11. University Cardiologic Centre, University Hospital of Ferrara, Ferrara, Italy. 12. Cardiology, DIMES, Alma Mater-University of Bologna, Bologna, Italy.
Abstract
BACKGROUND: A new class of drugs-angiotensin receptor, neprylisin inhibitors, ARNI-has shown to be prognostic superior in HFrEF to the sole inhibition of the renin-angiotensin axes with enalapril. The ultimate mechanism of action of ARNIs is unknown. AIM: We have considered that ARNI exerts a positive modulation of the neuroendocrine balance, with enhancement of the physiological diuresis and dilatation due to neprylisin inhibition by sacubitril. This represents a shift in HF medical therapy always directed to counteract (with inhibitors of the renin-angiotensin system, beta blockers or inhibitors of aldosterone) the so-called "bad" neuroendocrine response. Development of ARNI, on the contrary, has led to consider the neuroendocrine response to HFrEF from a different angle, which is to say that the activation is not always deleterious, but it could also be beneficial. This concept is highlighted by the enhancement of the activity of atrial natriuretic peptide, induced by sacubitril/valsartan in the PARADIGM trial, and found as proof from early studies on untreated patients with constrictive pericarditis. The possibility that sacubitril inhibition of neprylisin acts by enhancing substance P and gene-related calcitonin peptide is also considered, as well as the negative effect of neprylisin inhibition. CONCLUSIONS: The beneficial effects of ARNI are related, in part at least, to a positive modulation of the neuroendocrine response to the disease, resulting in an increase of physiological diuresis and dilatation.
BACKGROUND: A new class of drugs-angiotensin receptor, neprylisin inhibitors, ARNI-has shown to be prognostic superior in HFrEF to the sole inhibition of the renin-angiotensin axes with enalapril. The ultimate mechanism of action of ARNIs is unknown. AIM: We have considered that ARNI exerts a positive modulation of the neuroendocrine balance, with enhancement of the physiological diuresis and dilatation due to neprylisin inhibition by sacubitril. This represents a shift in HF medical therapy always directed to counteract (with inhibitors of the renin-angiotensin system, beta blockers or inhibitors of aldosterone) the so-called "bad" neuroendocrine response. Development of ARNI, on the contrary, has led to consider the neuroendocrine response to HFrEF from a different angle, which is to say that the activation is not always deleterious, but it could also be beneficial. This concept is highlighted by the enhancement of the activity of atrial natriuretic peptide, induced by sacubitril/valsartan in the PARADIGM trial, and found as proof from early studies on untreated patients with constrictive pericarditis. The possibility that sacubitril inhibition of neprylisin acts by enhancing substance P and gene-related calcitonin peptide is also considered, as well as the negative effect of neprylisin inhibition. CONCLUSIONS: The beneficial effects of ARNI are related, in part at least, to a positive modulation of the neuroendocrine response to the disease, resulting in an increase of physiological diuresis and dilatation.
Authors: K S Kirkwood; N W Bunnett; J Maa; I Castagliolo; B Liu; N Gerard; J Zacks; C Pothoulakis; E F Grady Journal: Am J Physiol Gastrointest Liver Physiol Date: 2001-08 Impact factor: 4.052
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Carol I Duffy; Andrew P Ambrosy; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: N Engl J Med Date: 2018-11-11 Impact factor: 91.245
Authors: Susan Stienen; Patrick Rossignol; António Barros; Nicolas Girerd; Bertram Pitt; Faiez Zannad; João Pedro Ferreira Journal: Clin Res Cardiol Date: 2019-06-27 Impact factor: 5.460
Authors: Milton Packer; Robert M Califf; Marvin A Konstam; Henry Krum; John J McMurray; Jean-Lucien Rouleau; Karl Swedberg Journal: Circulation Date: 2002-08-20 Impact factor: 29.690
Authors: Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong Journal: Circulation Date: 2014-11-17 Impact factor: 29.690
Authors: Thomas Münzel; Omar Hahad; Tommaso Gori; Sebastian Hollmann; Natalie Arnold; Jürgen H Prochaska; Andreas Schulz; Manfred Beutel; Norbert Pfeiffer; Irene Schmidtmann; Karl J Lackner; John F Keaney; Philipp S Wild Journal: Clin Res Cardiol Date: 2019-04-05 Impact factor: 5.460